Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Centre, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, SE-413 45, Sweden.
BMC Med Imaging. 2012 May 30;12:12. doi: 10.1186/1471-2342-12-12.
Animal models are frequently used to assess new treatment methods in cancer research. MRI offers a non-invasive in vivo monitoring of tumour tissue and thus allows longitudinal measurements of treatment effects, without the need for large cohorts of animals. Tumour size is an important biomarker of the disease development, but to our knowledge, MRI based size measurements have not yet been verified for small tumours (10-2-10-1 g). The aim of this study was to assess the accuracy of MRI based tumour size measurements of small tumours on mice.
2D and 3D T2-weighted RARE images of tumour bearing mice were acquired in vivo using a 7 T dedicated animal MR system. For the 3D images the acquired image resolution was varied. The images were exported to a PC workstation where the tumour mass was determined assuming a density of 1 g/cm(3), using an in-house developed tool for segmentation and delineation. The resulting data were compared to the weight of the resected tumours after sacrifice of the animal using regression analysis.
Strong correlations were demonstrated between MRI- and necropsy determined masses. In general, 3D acquisition was not a prerequisite for high accuracy. However, it was slightly more accurate than 2D when small (<0.2 g) tumours were assessed for inter- and intraobserver variation. In 3D images, the voxel sizes could be increased from 1603 μm(3) to 2403 μm(3) without affecting the results significantly, thus reducing acquisition time substantially.
2D MRI was sufficient for accurate tumour size measurement, except for small tumours (<0.2 g) where 3D acquisition was necessary to reduce interobserver variation. Acquisition times between 15 and 50 minutes, depending on tumour size, were sufficient for accurate tumour volume measurement. Hence, it is possible to include further MR investigations of the tumour, such as tissue perfusion, diffusion or metabolic composition in the same MR session.
动物模型经常被用于癌症研究中的新治疗方法的评估。磁共振成像(MRI)提供了对肿瘤组织的非侵入性体内监测,从而允许对治疗效果进行纵向测量,而无需大量动物。肿瘤大小是疾病发展的重要生物标志物,但据我们所知,MRI 基于的肿瘤大小测量尚未在小肿瘤(10-2-10-1 g)上得到验证。本研究的目的是评估基于 MRI 的小肿瘤大小测量的准确性。
使用 7 T 专用动物磁共振系统在体获得荷瘤小鼠的 2D 和 3D T2 加权 RARE 图像。对于 3D 图像,改变了采集的图像分辨率。将图像导出到 PC 工作站,使用内部开发的分割和描绘工具,假设密度为 1 g/cm3,确定肿瘤质量。使用回归分析将得到的数据与动物处死时切除肿瘤的重量进行比较。
MRI 和解剖确定的质量之间显示出很强的相关性。一般来说,3D 采集不是高精度的先决条件。然而,当评估小肿瘤(<0.2 g)的内和观察者间变化时,3D 采集比 2D 稍微更准确。在 3D 图像中,体素大小可以从 1603 μm3 增加到 2403 μm3,而不会显著影响结果,从而大大减少采集时间。
2D MRI 足以进行准确的肿瘤大小测量,除了小肿瘤(<0.2 g)需要 3D 采集来减少观察者间变化。根据肿瘤大小,15 至 50 分钟的采集时间足以进行准确的肿瘤体积测量。因此,有可能在同一磁共振检查中包括对肿瘤的进一步磁共振研究,如组织灌注、扩散或代谢组成。